Clinical Trial Update: Evaluation of Optimal Dosing Conditions for GLP-1 Analogue NNC0113-0987 When Administered Orally in Healthy Male Subjects [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluates optimal oral dosing conditions for the GLP-1 analogue NNC0113-0987 in healthy male volunteers. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• NNC0113-0987

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Healthy | Phase 1 | Status: COMPLETED